News Merck makes its move: Keytruda filed for first line lung can... Merck steals a march on rival BMS.
Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
Partner Content Partner Content The HNSCC immunotherapy race is on - and it's going to be cl... While improper to compare life saving treatments to buses - the metaphor when it comes to head and neck squamous cell carcinoma (HNSCC) is clear.
Cancer FDA accepts Keytruda head and neck cancer filing Merck's PD-1 inhibitor Keytruda (pembrolizumab) has been accepted for priority review by the FDA in another new setting, head and neck cancer.
News FDA clears Sanofi's Type 3 Gaucher therapy Infilbray Sanofi's Infilbray has become the first drug to treat neurological symptoms of rare lysosomal storage disorder Type 3 Gaucher disease (GD3) in the US.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.